BACKGROUND: The continued development of targeted therapeutics for cancer treatment has required the concomitant development of more expansive methods for the molecular profiling of the patient's tumor. We describe the validation of the JAX Cancer Treatment Profile™ (JAX-CTP™), a next generation sequencing (NGS)-based molecular diagnostic assay that detects actionable mutations in solid tumors to inform the selection of targeted therapeutics for cancer treatment. METHODS: NGS libraries are generated from DNA extracted from formalin fixed paraffin embedded tumors. Using hybrid capture, the genes of interest are enriched and sequenced on the Illumina HiSeq 2500 or MiSeq sequencers followed by variant detection and functional and clinical annotation for the generation of a clinical report. RESULTS: The JAX-CTP™ detects actionable variants, in the form of single nucleotide variations and small insertions and deletions (≤50 bp) in 190 genes in specimens with a neoplastic cell content of ≥10%. The JAX-CTP™ is also validated for the detection of clinically actionable gene amplifications. CONCLUSIONS: There is a lack of consensus in the molecular diagnostics field on the best method for the validation of NGS-based assays in oncology, thus the importance of communicating methods, as contained in this report. The growing number of targeted therapeutics and the complexity of the tumor genome necessitate continued development and refinement of advanced assays for tumor profiling to enable precision cancer treatment.
BACKGROUND: The continued development of targeted therapeutics for cancer treatment has required the concomitant development of more expansive methods for the molecular profiling of the patient's tumor. We describe the validation of the JAX Cancer Treatment Profile™ (JAX-CTP™), a next generation sequencing (NGS)-based molecular diagnostic assay that detects actionable mutations in solid tumors to inform the selection of targeted therapeutics for cancer treatment. METHODS: NGS libraries are generated from DNA extracted from formalin fixed paraffin embedded tumors. Using hybrid capture, the genes of interest are enriched and sequenced on the Illumina HiSeq 2500 or MiSeq sequencers followed by variant detection and functional and clinical annotation for the generation of a clinical report. RESULTS: The JAX-CTP™ detects actionable variants, in the form of single nucleotide variations and small insertions and deletions (≤50 bp) in 190 genes in specimens with a neoplastic cell content of ≥10%. The JAX-CTP™ is also validated for the detection of clinically actionable gene amplifications. CONCLUSIONS: There is a lack of consensus in the molecular diagnostics field on the best method for the validation of NGS-based assays in oncology, thus the importance of communicating methods, as contained in this report. The growing number of targeted therapeutics and the complexity of the tumor genome necessitate continued development and refinement of advanced assays for tumor profiling to enable precision cancer treatment.
Authors: Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo Journal: Genome Res Date: 2010-07-19 Impact factor: 9.043
Authors: Douglas B Johnson; Kimberly H Dahlman; Jared Knol; Jill Gilbert; Igor Puzanov; Julie Means-Powell; Justin M Balko; Christine M Lovly; Barbara A Murphy; Laura W Goff; Vandana G Abramson; Marta A Crispens; Ingrid A Mayer; Jordan D Berlin; Leora Horn; Vicki L Keedy; Nishitha M Reddy; Carlos L Arteaga; Jeffrey A Sosman; William Pao Journal: Oncologist Date: 2014-05-05
Authors: Birgitte B Simen; Lina Yin; Chirayu P Goswami; Kathleen O Davis; Renu Bajaj; Jerald Z Gong; Stephen C Peiper; Erica S Johnson; Zi-Xuan Wang Journal: Arch Pathol Lab Med Date: 2014-10-30 Impact factor: 5.534
Authors: Ben Tran; Andrew M K Brown; Philippe L Bedard; Eric Winquist; Glenwood D Goss; Sebastien J Hotte; Stephen A Welch; Hal W Hirte; Tong Zhang; Lincoln D Stein; Vincent Ferretti; Stuart Watt; Wei Jiao; Karen Ng; Sangeet Ghai; Patricia Shaw; Teresa Petrocelli; Thomas J Hudson; Benjamin G Neel; Nicole Onetto; Lillian L Siu; John D McPherson; Suzanne Kamel-Reid; Janet E Dancey Journal: Int J Cancer Date: 2012-10-11 Impact factor: 7.396
Authors: Jason Li; Richard Lupat; Kaushalya C Amarasinghe; Ella R Thompson; Maria A Doyle; Georgina L Ryland; Richard W Tothill; Saman K Halgamuge; Ian G Campbell; Kylie L Gorringe Journal: Bioinformatics Date: 2012-04-02 Impact factor: 6.937
Authors: Daniela Egas-Bejar; Pete M Anderson; Rishi Agarwal; Fernando Corrales-Medina; Eswaran Devarajan; Winston W Huh; Robert E Brown; Vivek Subbiah Journal: Oncoscience Date: 2014-03-12
Authors: Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean Journal: Nature Date: 2012-11-01 Impact factor: 49.962
Authors: Paul A VanderLaan; Deepa Rangachari; Susan M Mockus; Vanessa Spotlow; Honey V Reddi; Joan Malcolm; Mark S Huberman; Loren J Joseph; Susumu S Kobayashi; Daniel B Costa Journal: Lung Cancer Date: 2017-01-25 Impact factor: 5.705
Authors: Laura J Tafe; Kristen E Muller; Guruprasad Ananda; Talia Mitchell; Vanessa Spotlow; Sara E Patterson; Gregory J Tsongalis; Susan M Mockus Journal: Am J Pathol Date: 2016-01-18 Impact factor: 4.307
Authors: Sara E Patterson; Rangjiao Liu; Cara M Statz; Daniel Durkin; Anuradha Lakshminarayana; Susan M Mockus Journal: Hum Genomics Date: 2016-01-16 Impact factor: 4.639
Authors: Karen L Kaul; Linda M Sabatini; Gregory J Tsongalis; Angela M Caliendo; Randall J Olsen; Edward R Ashwood; Sherri Bale; Robert Benirschke; Dean Carlow; Birgit H Funke; Wayne W Grody; Randall T Hayden; Madhuri Hegde; Elaine Lyon; Kazunori Murata; Melissa Pessin; Richard D Press; Richard B Thomson Journal: Acad Pathol Date: 2017-07-16